An Individual Patient Data Metaanalysis of Outcomes and Prognostic Factors After Treatment of Oligometastatic Non–Small-Cell Lung Cancer
A. Ashworth(London Health Sciences Centre), George Rodrigues(London Health Sciences Centre), Tommaso Martino De Pas(European Institute of Oncology), Daniel R. Gomez(The University of Texas MD Anderson Cancer Center), Maria Teresa Congedo(Università Cattolica del Sacro Cuore), Umberto Ricardi(University of Turin), Claudio V. Sole, Suresh Senan(Amsterdam UMC Location VUmc), Michael T. Milano(University of Rochester), David A. Palma(Western University), Yong Chan Ahn(Samsung Medical Center), Dennis L. Carter(Rocky Mountain Cancer Centers), Marc Riquet(Hôpital Européen Georges-Pompidou), Gavin Wright(The University of Melbourne), Andrew J. Warner(London Health Sciences Centre), Giulio Melloni(San Raffaele University of Rome)
Cited by 437
Related Papers
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
|The Lancet|2019|1.9k
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study
|Journal of Clinical Oncology|2019|1.3k
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
|Journal of Clinical Oncology|2020|1.2k
Prophylactic Cranial Irradiation in Extensive Small-Cell Lung Cancer
|New England Journal of Medicine|2007|1.1k